Background: Prostate biopsy is a main way for cancer detection and management, which is commonly performed in clinic and over 1 million procedures performed per year in Europe and the united states. The potential for biobanking of these specimens as valuable addition Methods: After informed consent as part of an IRB approved protocol, ultrasound-guided biopsies of prostate cancer loci were performed on 18 consecutive cancer patients. Each locus is repeated biopsy and fresh tissues were transported on wet ice to Pathology and Center for Translational Medicine. After confirmation and evaluation of tumor content by professional pathologist, a minimum of 30 ng DNA of repeated biopsy loci was extracted for sequencing. Corresponding germline DNA from blood is extracted and used to prepare sequencing libraries for
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